Dr Jacob D Soumerai and Prof Andrew D Zelenetz discuss their phase 2 trial of the BOVen regimen and MRD-driven treatment discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma. Read the full article: <a href='https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00307-0/fulltext'>https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00307-0/fulltext</a>

Lan-Lan Smith, Editor-in-Chief of The Lancet Haematology, and the journal’s authors explore their research and its impact on people’s health, health care, and health policy in this regular podcast.